TY - JOUR
T1 - High levels of fecal calprotectin and C-reactive protein in patients with colitis
AU - Anindita, Brinna
AU - Sugihartono, Titong
AU - Miftahussurur, Muhammad
AU - Maimunah, Ummi
AU - Nusi, Iswan Abbas
AU - Setiawan, Poernomo Boedi
AU - Purbayu, Herry
AU - Kholili, Ulfa
AU - Widodo, Budi
AU - Thamrin, Husin
AU - Vidyani, Amie
AU - Rezkitha, Yudith Annisa Ayu
AU - Yamaoka, Yoshio
N1 - Publisher Copyright:
© 2023 JOURNAL of MEDICINE and LIFE.
PY - 2023
Y1 - 2023
N2 - Inflammatory bowel disease (IBD) with a poor prognosis may be due to persistent colitis. According to the latest guidelines, monitoring has become a part of the treatment process for colitis. Adequate monitoring of the patient's condition is necessary to determine the course of the disease to prevent the worsening of the condition and suppress the subclinical inflammatory process. This analytical study with a cross-sectional design was conducted to evaluate the activity of colitis using the results of C-reactive protein (CRP) and fecal calprotectin (FC) assays. FC levels were analyzed by ELISA, while CRP levels were analyzed using Siemens Flex particle-enhanced turbidimetric immunoassay. In 30 subjects with endoscopy and biopsy of colitis, 16 men and 14 women had a median age of 52.5 (18–70) years. The median FC value increased by 67 (7.3–722 g/g) and was positive (≥50 g/g) in 20 subjects (66.7%), and the mean CRP value was 13.64 mg/L, positive (10–15 mg/L) in 13 subjects (43.33%), and negative (<10 mg/L) in 17 subjects (56.67%). This study demonstrated that FC had a significant relationship with CRP (r=0.57; p<0.001) in patients with colitis. Assessing the levels of FC and CRP among patients with colitis can be useful to assess the worsening of symptoms early and reduce mortality and morbidity.
AB - Inflammatory bowel disease (IBD) with a poor prognosis may be due to persistent colitis. According to the latest guidelines, monitoring has become a part of the treatment process for colitis. Adequate monitoring of the patient's condition is necessary to determine the course of the disease to prevent the worsening of the condition and suppress the subclinical inflammatory process. This analytical study with a cross-sectional design was conducted to evaluate the activity of colitis using the results of C-reactive protein (CRP) and fecal calprotectin (FC) assays. FC levels were analyzed by ELISA, while CRP levels were analyzed using Siemens Flex particle-enhanced turbidimetric immunoassay. In 30 subjects with endoscopy and biopsy of colitis, 16 men and 14 women had a median age of 52.5 (18–70) years. The median FC value increased by 67 (7.3–722 g/g) and was positive (≥50 g/g) in 20 subjects (66.7%), and the mean CRP value was 13.64 mg/L, positive (10–15 mg/L) in 13 subjects (43.33%), and negative (<10 mg/L) in 17 subjects (56.67%). This study demonstrated that FC had a significant relationship with CRP (r=0.57; p<0.001) in patients with colitis. Assessing the levels of FC and CRP among patients with colitis can be useful to assess the worsening of symptoms early and reduce mortality and morbidity.
KW - CRP
KW - colitis
KW - fecal calprotectin
KW - inflammatory bowel disease
UR - http://www.scopus.com/inward/record.url?scp=85149570309&partnerID=8YFLogxK
U2 - 10.25122/jml-2021-0311
DO - 10.25122/jml-2021-0311
M3 - Article
C2 - 36873123
AN - SCOPUS:85149570309
SN - 1844-122X
VL - 16
SP - 48
EP - 51
JO - Journal of medicine and life
JF - Journal of medicine and life
IS - 1
ER -